Magnetic Resonance Spectroscopy Findings and Cognitive Function in Patients with Parkinson’s disease
International Clinical Neuroscience Journal,
Vol. 4 No. 2 (2017),
12 June 2017
Background and Purpose: Cognitive impairment (CI) is one of the most notable disabilities of Parkinson’s disease that is associated with lower quality of life. Early detection of CI is therefore very important for these patients. The purpose of this study was to examine the relationship between cognitive function and the metabolic data from magnetic resonance spectroscopy (MRS) of the patient suffering with Parkinson’s disease.
Methods: Totally, 45 patients with Parkinson’s disease were used in this study. Subjects were divided into three groups based on scales for outcome from Parkinson cognition (SCOPA-COG) test. Patients were classified as non-cognitive impairment (NCI; n=15), mild cognitive impairment (MCI; n=15) and dementia (PDD; n=15). All subjects underwent MRI and 1H-MRS techniques and metabolic changes such as NAA/Cr and NAA/Cho ratios, which were measured in the left hippocampal area of the brain.
Results: The mean and standard deviation of the NAA/Cr ratio in the three cognitive groups (NCI, MCI, PDD) were (2.51±0.037), (2.50±0.033) and (2.47±0.025), respectively. ANOVA test showed a significant difference in the three groups. Furthermore, the Scheffé test showed a significant difference between patients in the MCI and PDD groups (p=0.01). There was no significant difference between the non-cognitive impairment and mild cognitive impairment groups (p=0.54). No significant difference was found in NAA/Cho ratio (p=091).
Conclusion: A decreasing NAA/Cr ratio has influence on cognitive function and the development of severe cognitive dysfunction in Parkinson suffering patients. Furthermore, 1H-MRS determinant can be useful to evaluate cognition in Parkinson patients.
- Magnetic resonance spectroscopy
- cognitive function
- Parkinson’s disease
How to Cite
Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? Journal of Neurology, Neurosurgery & Psychiatry. 2000;69(3):308-12.
Chaudhuri K, Martinez‐Martin P. Quantitation of non‐motor symptoms in Parkinson’s disease. European Journal of Neurology. 2008;15(s2):2-8.
Kim H-J, Park S-Y, Cho Y-J, Hong K-S, Cho J-Y, Seo S-Y, et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. Journal of the neurological sciences. 2009;287(1):200-4.
Muslimović D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239-45.
Caviness JN, Driver‐Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson's disease. Movement Disorders. 2007;22(9):1272-7.
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease A multicenter pooled analysis. Neurology. 2010;75(12):1062-9.
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Movement Disorders. 2008;23(6):837-44.
Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. The Lancet Neurology. 2012;11(8):697-707.
Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson's disease is associated with hippocampal atrophy. Movement Disorders. 2003;18(7):784-90.
Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. Journal of Neurology, Neurosurgery & Psychiatry. 2007;78(3):254-9.
Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, Duda JE, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Archives of neurology. 2011;68(12):1562-8.
Tumati S, Martens S, Aleman A. Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2013;37(10):2571-86.
Summerfield C, Gómez-Ansón B, Tolosa E, Mercader JM, Martí MJ, Pastor P, et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Archives of neurology. 2002;59(9):1415-20.
Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Disease & Associated Disorders. 2008;22(1):54-60.
Johnson DK GJ. Longitudinal changes in cognition in Parkinson’s disease with and without dementia. Dement Geriatr Cogn Disord. 2011;10.
Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch J, Evans A, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology. 2005;64(2):224-9.
Verbaan D, Marinus J, Visser M, Van Rooden S, Stiggelbout A, Middelkoop H, et al. Cognitive impairment in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2007;78(11):1182-7.
Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127(3):550-60.
Isella V, Mapelli C, Morielli N, Siri C, De Gaspari D, Pezzoli G, et al. Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog. Parkinsonism & related disorders. 2013;19(12):1160-3.
Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Journal of neurology. 2008;255(2):255-64.
Aarsland D, Andersen K, Larsen JP, Lolk A. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Archives of neurology. 2003;60(3):387-92.
Metastasio A, Rinaldi P, Tarducci R, Mariani E, Feliziani FT, Cherubini A, et al. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiology of aging. 2006;27(7):926-32.
Benarroch EE. N-Acetylaspartate and N-acetylaspartylglutamate Neurobiology and clinical significance. Neurology. 2008;70(16):1353-7.
Chaudhuri K, Lemmens G, Williams S, Ellis C, Lloyd C, Dawson J, et al. Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations. Parkinsonism & related disorders. 1996;2(2):63-7.
Tedeschi G, Litvan I, Bonavita S, Bertolino A, Lundbom N, Patronas N, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain. 1997;120(9):1541-52.
Wang Z, Zhao C, Yu L, Zhou W, Li K. Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease. Acta Radiologica. 2009;50(3):312-9.
Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res. 2004;1003(1-2):26-35.
Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A. Grey Matter Changes in Cognitively Impaired Parkinson's Disease Patients. PloS one. 2014;9(1):e85595.
Passani LA, Vonsattel JPG, Carter RE, Coyle JT. N-acetylaspartylglutamate, N-acetylaspartate, andN-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer diseases. Molecular and chemical neuropathology. 1997;31(2):97-118.
Bast T. The hippocampal learning-behavior translation and the functional significance of hippocampal dysfunction in schizophrenia. Current opinion in neurobiology. 2011;21(3):492-501.
Sweatt JD. Hippocampal function in cognition. Psychopharmacology. 2004;174(1):99-110.
Valenzuela MJ, Jones M, Rae WWC, Graham S, Shnier R, Sachdev P. Memory training alters hippocampal neurochemistry in healthy elderly. Neuroreport. 2003;14(10):1333-7.
Frodl T, Schaub A, Banac S, Charypar M, Jäger M, Kümmler P, et al. Reduced hippocampal volume correlates with executive dysfunctioning in major depression. Journal of Psychiatry and Neuroscience. 2006;31(5):316.
- Abstract Viewed: 388 times
- PDF Downloaded: 335 times